Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ThredUp Inc (TDUP) vs GeneDx Holdings Corp (WGS) Price & Performance

ThredUp IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

ThredUp Inc vs GeneDx Holdings Corp — how do they compare? ThredUp Inc trades at $6.44 (market cap $850.38M), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: GeneDx Holdings Corp is far larger — about 2.1× ThredUp Inc's market cap, and ThredUp Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

TDUPWGS
Market Cap
$850.38M$1.80B
Sector
Consumer CyclicalTechnology
52-Week High
$12.08$167.51
52-Week Low
$3.11$34.51
Enterprise Value
$853.11M$1.80B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ThredUp Inc

TDUP trades at $6.43, down 2.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, but posted a net loss of $20.21 million for 2025. Analyst consensus is bullish with a $6.90 price target, and recent news highlights AI integration and a new peer-to-peer marketplace launch.

The outlook remains cautiously optimistic due to strong revenue growth and improving gross margins, but persistent net losses and negative ROE pose significant risks. Investment opportunity lies in operational efficiency gains from AI, while key risks include sustained unprofitability and competitive pressures in online resale.

GeneDx Holdings Corp

GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.

Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.

Returns comparison

Trailing returns across standard periods

About ThredUp Inc

ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.

Read more on TDUP

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS